Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Schizophrenia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Schizophrenia
    Schizophrenia and Bipolar Disorder Share Genetic Roots, Researchers Find - (DGNews)
    Long-Acting Risperidone Shows Benefits in Recent-Onset Schizophrenia: Presented at WCBP - (DGDispatch)
    Injectable Risperidone Superior to Oral Quetiapine in Stable Patients With Schizophrenia Who Need Treatment Switch: Presented at WCBP - (DGDispatch)
    TopAbstracts in Schizophrenia 06/25/2009 - (DGNews)
    TopAbstracts in Schizophrenia 06/11/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Schizophrenia
    • Major Depression and Psychoses: Screening, Accurately Diagnosing, and Properly Managing in Primary Care
    • Consistent Approach and Assessment Tools Aid Screening for Major Depressive Disorder and Psychosis in Primary Care
    • Navigating Differential Diagnosis in Major Depressive Disorder: The Role of the Primary Care Physician
    • Newer Classes Enhance Traditional Antidepressants and Are Preferred First-Line Therapies in Primary Care
    • Optimizing the Management of Schizophrenia: Evidence-Based Methods to Minimize the Burden of Disease in Managed Care

      Webcasts/CME archive

       Recent cases - Schizophrenia
        Localisation Using Mini C-Arm Fluoroscopy of Needles Ingested by a Woman with Schizophrenia: A Case Report
        Schizophrenia Spectrum Disorders in a Nigerian Family: 4 Case Reports
        Massive Pulmonary Emboli Associated with Olanzapine
        Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
        Diabetic Control and Atypical Antipsychotics: A Case Report

        Cases archive
          




        my personal edition > schizophrenia > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Patients with Schizophrenia Unlikely to Respond to Treatment Within 4 Weeks if No Response Noted at 1 Week

        A DGReview of :"Early prediction of antipsychotic response in schizophrenia"
        American Journal of Psychiatry

        11/10/2003
        By Emma Hitt, PhD


        Patients with minimal improvement in schizophrenic symptoms during the first week of treatment with a typical antipsychotic are unlikely to respond within 4 weeks, new research suggests.

        To facilitate rapid discharge from inpatient settings, the current managed care environment often dictates a change of antipsychotic medication days after initiation in "nonresponsive" patients. "Unfortunately, there are few empirical data to support this practice," note Christoph U. Correll, MD, with the Hillside Hospital, Glen Oaks, New York, United States, and colleagues.

        In their study, 131 acutely ill patients with schizophrenia received 4 weeks of fluphenazine treatment. Brief Psychiatric Rating Scale (BPRS) scores were measured at baseline and each week for 4 weeks.

        The relationship between changes in BPRS total score and each factor score following 1 week of treatment were evaluated. Ultimate antipsychotic response was defined as a reduction of 20% or more in the total BPRS baseline score at 4 weeks.

        Every patient who displayed an improvement of less than 20% in BPRS total score and 95% of patients who displayed a reduction of less than 20% in BPRS thought disturbance factor score following 1 week of treatment were found to be nonresponders after 4 weeks of treatment, they report.

        "These data suggest that patients with minimal improvement in positive symptoms during the first week of treatment with a typical antipsychotic are unlikely to respond to a 4-week trial," Dr. Correll and colleagues conclude. "These data require confirmation and extension to studies with second-generation antipsychotics," they add.

        According to the researchers, early BPRS ratings may be useful in identifying nonresponders as early as 7 days into treatment, and could provide the basis for changing antipsychotic treatment. "Furthermore, since symptoms were rated weekly, we cannot exclude that symptom improvement before day 7 of antipsychotic treatment may be as reliable or even more reliable as a predictor than improvement at 1 week," they add.

        Am J Psychiatry 2003 Nov;160:11:2063-2065. "Early prediction of antipsychotic response in schizophrenia"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send